Willow Biosciences Reports First Quarter 2021 Results, an Operational Update and the Addition of a New Board Member
News provided by
Share this article
Willow or the
Company ) (TSX: WLLW) (OTCQX: CANSF) has released its financial and operating results for the three months ended March 31, 2021, reporting significant advancement in its operations and strong liquidity. The first quarter represented another significant move forward for us, as we completed our first commercial scale fermentation run and strengthened our balance sheet for success, said Trevor Peters, Willow s President and Chief Executive Officer. We are entering the next phase for the Company, which is creating new markets for our ultra-pure, sustainably made, cannabinoids, and our world class team has allowed us to be at the forefront of the industry. As the industry continues to move towards increased regulation from a health and safety perspective, there is a need now more than ever for Willow s consistent
Willow Biosciences Inc. (
Willow or the
Company ) (TSX: WLLW) (OTCQX: CANSF) is pleased to announce that it has completed a series of studies with its development partner, Signum Biosciences, Inc., that demonstrate the safety and anti-inflammatory, anti-aging, and antimicrobial properties of Willow s cannabigerol (
Willow
CBG ). The studies demonstrate that Willow CBG is safe when applied to skin and eye areas and can act as a more potent antioxidant and anti-inflammatory for certain skin applications when compared to plant derived cannabidiol (
CBD ), as further described below. Demonstrating the safety and benefit of a new ingredient like Willow s CBG is a critical step in commercialization and it s one that we take seriously at the Company, said Dr. Chris Savile, Willow s Chief Operating Officer. Willow s CBG is now clinically tested to be safe for sensitive skin and demonstrated in the laboratory to act as a potent antioxidant, anti-inflammatory and anti-micro